Wilson Sonsini Goodrich & Rosati is pleased to support LaunchBio’s Larger Than Life Science: Opportunities and Challenges in the Early Development of Immuno-Oncology Therapies.  Evasion or inhibition of immune surveillance has been shown to be a major mechanism limiting the effectiveness of traditional therapies against tumor cells. However, recent breakthroughs in immuno-oncology research have established that harnessing of the immune system is a powerful way to combat cancer. This panel discussion will address key considerations and challenges in immuno-oncology drug development from discovery research to nonclinical safety assessment.  Key areas of discussion will focus on the pros and cons of different animal models based on mechanism of action, identifying the best study design and endpoints based on target, and key considerations when developing a pre-clinical safety assessment strategy to support the first in human clinical trial.